FDA Drug Safety Podcast: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death

On November 6, 2015 FDA announced that a review has determined that long-term use of the blood-thinning drug Plavix (active ingredient clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease.
Source: FDA Drug Safety Podcasts